Secretive Theracos seeks niche in SGLT2 class
This article was originally published in Scrip
With two SGLT2 inhibitors approved in the US and a third that may be able to overcome its recent US FDA rejection, it remains to be seen whether the type 2 diabetes market needs another drug in that class, but privately-held Theracos believes it has a differentiated product candidate that could overcome certain side effects.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.